ScholarLens Back to search
2017•NeurologyRequires access

Comparison of Natalizumab vs Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience (S31.006)

Brandi L. Vollmer, Kavita V Nair, Stefan Sillau, John R. Corboy, Timothy R. Vollmer, Enrique Álvarez

Open publisher page 0 citations

Abstract

Compare two year discontinuation rates and efficacy of fingolimod(FTY) and dimethyl fumarate(DMF) to natalizumab(NTZ).

About this research paper

What this paper is about

Compare two year discontinuation rates and efficacy of fingolimod(FTY) and dimethyl fumarate(DMF) to natalizumab(NTZ).

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Compare two year discontinuation rates and efficacy of fingolimod(FTY) and dimethyl fumarate(DMF) to natalizumab(NTZ).

Key concepts: Natalizumab, Fingolimod, Dimethyl fumarate, Multiple sclerosis, Medicine, Dermatology, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparison of Natalizumab vs Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience (S31.006) — Research Paper | ScholarLens